Research article · 9 Sep 2016
Conference abstractPublished 26 Sep 2019
Immunogenic cell death in cancer and infectious disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Immunogenicity depends on two key factors: antigenicity and adjuvanticity. The presence of exogenous or mutated antigens explains why infected cells and malignant cells can initiate an adaptive immune response provided that the cells also emit adjuvant signals as a consequence of cellular stress and death. Several infectious pathogens have devised strategies to control cell death and limit the emission of danger signals from dying cells, thereby avoiding immune recognition. Similarly, cancer cells often escape immunosurveillance owing to defects in the molecular machinery that underlies the release of endogenous adjuvants. Conventional chemotherapeutics and targeted antineoplastic agents have been developed based on the simplistic notion that cancer constitutes a cell-autonomous genetic or epigenetic disease. Nonetheless, it is becoming clear that many of the available anticancer drugs that have collectively saved millions of life-years mediate therapeutic effects by eliciting de novo or reactivating preexisting tumor-specific immune responses. I will discuss the capacity of anticancer therapies to enhance the immunogenic properties of malignant cells and to stimulate immune effector cells, either directly or by subverting the immunosuppressive circuitries that preclude antitumor immune responses in cancer patients. Accumulating evidence indicates that the therapeutic efficacy of many (if not most) antineoplastic agents relies on their capacity to influence the tumor-host interaction, tipping the balance toward the activation of an immune response specific for malignant cells. One particular way to reinstate immunosurveillance consists in the induction of immunogenic cell death (ICD), which involves elements of organelle-specific, autophagic, apoptotic and necroptotic stress signaling. ICD involves changes in the composition of the cell surface as well as the release of soluble mediators, occurring in a defined temporal sequence. Such signals operate on a series of receptors expressed by dendritic cells to stimulate the presentation of tumor antigens to T cells. We postulate that ICD constitutes a prominent pathway for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies. Hence, suboptimal regimens (failing to induce ICD), selective alterations in cancer cells (preventing the emission of immunogenic signals during ICD), or defects in immune effectors (abolishing the perception of ICD by the immune system) can all contribute to therapeutic failure.
Subjects
MicrobiologyInfectious DiseasesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 5 May 2023
Experimental Study on the Effect of Different Routes of Administration on the Immunogenicity of Live Infectious Bursal Disease Vaccine
Conference abstract · 5 Apr 2021
Bacteriology and Infectious Diseases 2018 - Role of human papillomavirus, estrogen and Apobec3B axis in breast cancer initiations
Short communication · 27 Jul 2020
Bacteriology and Infectious Diseases 2018 - Role of human papillomavirus, estrogen and Apobec3B axis in breast cancer initiation
Research article · 27 Jun 2023
Prevalence and Factors Associated with Death in Healthcare-Associated Bacteremia in the Fann National University Hospital, Infectious and Tropical Diseases Department
More from this journal
The newest in Clinical Microbiology: Open Access.
Article · 18 Dec 2025
Molecular and Proteomic Strategies for Reliable Microbial Identification
Article · 18 Dec 2025
Culture-Based and Molecular Assessment of Microbial Diversity
Article · 18 Dec 2025
Antimicrobial Resistance Detection and Microbial Identification
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Microbiology: Open Access
- SubjectMicrobiology
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Guido Kroemer”
